MDLinx Family Medicine stands out from other primary care literature review services because of our dedication to keeping our members current in less time. On a daily basis, receive an email with just the ‘headlines’ covering everything important that published in your specialty in the past 24 hours. Or, choose to Focus On the top articles published in the hottest topics in primary care, such as heart failure, depression, diabetes mellitus, eczema/psoriasis, infectious diseases, rheumatoid arthritis, COPD, and many more.
Additional bonus content is also available on this page, including clinical pearls from The Smartest Family Physician, a daily quiz competition from the editors of MDLinx Internal Medicine in collaboration with the Cleveland Clinic Center for Continuing Education. Additionally, enjoy the can’t-miss articles highlighted by our own physician editor, D. Scott Cunningham, MD, PhD.
Your Unread Messages in Family Medicine
See All >> Messages include industry-sponsored communications and special communications from MDLinx
Smartest Doc Challenge
MDLinx
Today Only! We're helping you prep for your board exams
D Scott Cunningham MD, PhD
Site Editor, MDLinx
Outcome in MI patients with hyponatremia
Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage
MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools
1 LDL cholesterol-lowering effects of grape extract used as a dietary supplement on healthy volunteers International Journal of Food Sciences and Nutrition, May 22, 2013 Clinical Article
2 Lipid-lowering pharmacotherapy and socioeconomic status: atherosclerosis risk in communities (ARIC) surveillance study Full Text BMC Public Health, May 22, 2013 Clinical Article
3 Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease Annals of Medicine, May 22, 2013 Review Article Clinical Article
4 A practical and effective low-intensity dietary counseling intervention for use in primary care patients with dyslipidemia - a randomized controlled pilot trial Full Text BMC Family Practice, May 22, 2013 Clinical Article
5 Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the Multi-Ethnic Study of Atherosclerosis European Journal of Preventive Cardiology, May 22, 2013 Clinical Article
6 Calcium co-ingestion augments postprandial glucose-dependent insulinotropic peptide1–42, glucagon-like peptide-1 and insulin concentrations in humans European Journal of Nutrition, May 22, 2013 Clinical Article
7 Comparison of Effects of Serum n-3 to n-6 Polyunsaturated Fatty Acid Ratios on Coronary Atherosclerosis in Patients Treated With Pitavastatin or Pravastatin Undergoing Percutaneous Coronary Intervention The American Journal of Cardiology, May 22, 2013 Clinical Article
8 NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis Circulation, May 22, 2013 Clinical Article
9 Age-dependent interaction of apolipoprotein E gene with eastern birthplace in Finland affects severity of coronary atherosclerosis and risk of fatal myocardial infarction-Helsinki Sudden Death Study Annals of Medicine, May 22, 2013 Evidence Based Medicine Clinical Article
10 Identification of candidate genes encoding an LDL-C QTL in baboons Journal of Lipid Research, May 22, 2013 Clinical Article
11 Rare APOA5 Promoter Variants Associated With Paradoxical HDL Cholesterol Decrease in Response to Fenofibric Acid Therapy Journal of Lipid Research, May 22, 2013 Clinical Article
12 Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients HIV Medicine, May 21, 2013 Clinical Article
13 Estimated Daily Flavonoid and Stilbene Intake from Fruits, Vegetables, and Nuts and Associations with Lipid Profiles in Chinese Adults Journal of the Academy of Nutrition and Dietetics, May 21, 2013 Clinical Article
14 Anti-Inflammatory Strategies for Plaque Stabilization after Acute Coronary Syndromes Current Atherosclerosis Reports, May 21, 2013 Clinical Article
15 LOX-1 ligands containing apolipoprotein B and carotid intima-media thickness in middle-aged community-dwelling US Caucasian and Japanese men Atherosclerosis, May 21, 2013 Clinical Article
16 Oxidized eicosapentaenoic acids more potently reduce LXRalpha-induced cellular triacylglycerol via suppression of SREBP-1c, PGC-1beta and GPA than its intact form Full Text Lipids in Health and Disease, May 21, 2013
17 Total and high molecular weight adiponectin levels and risk of cardiovascular disease in individuals with high blood glucose levels Atherosclerosis, May 20, 2013 Clinical Article
18 Imaging and management of atherosclerotic renal artery stenosis Clinical Radiology, May 20, 2013 Review Article
19 Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review Expert Review of Gastroenterology & Hepatology, May 20, 2013 Clinical Article
20 Present Status of the Standardization of HDL-C, LDL-C, and TG Measurement Values Available in Japan Journal of Clinical Laboratory Analysis, May 20, 2013 Clinical Article
In a 12-week randomized, controlled trial, ingestion of a vitamin D-fortified yogurt (170 mg calcium + 500 IU vitamin D/250 mL; n=50) twice daily decreased markers of inflammation compared with placebo yogurt (170 mg calcium; n=50). Compared with baseline measures, the 25(OH)D levels were increased and the TNF-alpha, IL-6, hsCRP, SAA, and IL-10 levels were decreased in the group supplemented with vitamin D compared with the group that received placebo.
Read the article summaryResearchers at the University of Palermo conducted a study involving 9109 subjects with a mean follow-up of 6.2 years which showed that the subjects who adhered to a Mediterranean diet had increased dietary fiber, decreased total dietary fat, and an increased intake of monosaturated-to-saturated fats. Further, the incidence of diabetes, cardiovascular events, and all-cause mortality was lower in the subjects who followed a Mediterranean diet.
Read the article summaryBased on a retrospective study conducted at the Federico II University (Naples), researchers have concluded that treatment of patients (n=84) with relapsing-remitting MS natalizumab for 12-24 months resulted in a greater reduction in disease activity (annualized relapse rate, .24 vs. .55, respectively) and disability progression than patients treated with INF-? 1a. The number of contrast-enhancing lesions was also less in the natalizumab-treated group.
Read the article summaryIndexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Med more
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close